Quercetin effectiveness in patients with COVID-19 associated pneumonia

Abstract

The aim of this work was to evaluate the effectiveness of quercetin addition to the treatment regimen for patients with COVID-19 associated pneumonia. Materials and methods. The effectiveness of two dosage forms of quercetin was studied in 200 patients, who were divided equally into the main and control groups. The main group patients received quercetin in addition to the basic therapy: intravenous drip of Quercetin/Polyvinylirolidone during the first 10 days followed by oral administration of Quercetin/Pectin over the next 10 days. Patients from the control group received only the basic therapy drugs. The study evaluated the dynamics of the disease symptoms (saturation level, respiratory rate, body temperature, cough, general weakness), as well as laboratory markers (C-reactive protein (CRP), ferritin, D-dimer). Results. Two dosage forms of quercetin consistently used in addition to the basic therapy improve pulmonary gas exchange and accelerate the lung function recovery. This is evidenced by a statistically significant majority of patients with positive dynamics in the symptoms of “Saturation level” and “Cough” as well as the meeting a complex indicator of the therapy effectiveness 2 days earlier than in the control group. The treatment regimen applied also helps to stabilize the level of D-dimer in the blood of the main group patients. Conclusions. The use of two dosage forms of quercetin in addition to the basic therapy accelerates the recovery of patients with coronavirus disease associated pneumonia and can help to prevent the progression of COVID-19 associated coagulopathy.

Quercetin for the treatment of COVID‐19 patients: A systematic review and meta‐analysis

“…Out of a total of 371 articles, we finally included 6 RCTs (933 patients) (Figure 1). [20][21][22][23][24]30 All RCTs were open-label, used various regiments and doses of quercetin (ranging from 260 to 1000 mg daily), and used standard care as the comparator. Details of each study are given in Table 1.…”

“…One trial was judged to be at a low risk of bias 24 while the rest had some concerns of bias mostly due to issues in the domain of randomisation process (Supplementary Figure ).…”

“…Quercetin, a flavanol found in many fruits (grape, apple, strawberry, cloudberry, and raspberry) and vegetables (onion, tomato, lettuce, and green bean), has been found to have powerful antioxidant, immunomodulatory and anti‐inflammatory properties 17–19 . As the clinical use of quercetin has been limited due to its low solubility and reduced absorption, it is available in numerous formulations to improve its bioavailability which include: quercetin phytosome, 20,21 curcumin, quercetin and cholecalciferol (CQC), 22 quercetin, vitamin C and bromelain (QCB), 23 and quercetin/pectin 24 . Usually, quercetin has been proposed as a therapy for cardiovascular diseases and cancers 25,26 .…”

“…[17][18][19] As the clinical use of quercetin has been limited due to its low solubility and reduced absorption, it is available in numerous formulations to improve its bioavailability which include: quercetin phytosome, 20,21 curcumin, quercetin and cholecalciferol (CQC), 22 quercetin, vitamin C and bromelain (QCB), 23 and quercetin/pectin. 24 Usually, quercetin has been proposed as a therapy for cardiovascular diseases and cancers. 25,26 However, several small trials investigating the efficacy of quercetin in COVID-19 patients have also been conducted now with inconsistent results.…”

Neglected Effective Early Therapies against COVID-19: Focus on Functional Foods and Related Active Substances. A Review

“…The already cited real time analysis of COVID-19 early (and late) treatments [21] shows for quercetin the following mortality results, all coming from single blind RCTs (Figure 5): [66][67][68][70][71][72][73][74][75][76]. This plot shows pooled effects, see the specific outcome analyses for individual outcomes, and the heterogeneity section [21] for discussion.…”